Advertisement

Resistance analysis in patients with genotype 1–6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies

Published:December 05, 2017DOI:https://doi.org/10.1016/j.jhep.2017.11.032

      Highlights

      • In patients with GT1-6 HCV infection, 28% had detectable NS5A class RASs at baseline.
      • High SVR rate was observed in patients treated with SOF/VEL irrespective of baseline NS5A RASs.
      • Single NS5A class resistance was observed at virologic failure post SOF/VEL treatment.

      Background & Aims

      The fixed-dose combination of sofosbuvir/velpatasvir was highly efficacious in patients infected with genotype (GT)1–6 hepatitis C virus (HCV) in the ASTRAL studies. This analysis evaluated the impact of baseline resistance-associated substitutions (RASs) on treatment outcome and emergence of RASs in patients infected with HCV GT1-6 who were treated with sofosbuvir/velpatasvir.

      Methods

      Non-structural protein 5A and 5B (NS5A and NS5B) deep sequencing was performed at baseline and at the time of relapse for all patients treated with sofosbuvir/velpatasvir for 12 weeks (n = 1,778) in the ASTRAL-1–3, ASTRAL-5 and POLARIS-2–3 studies.

      Results

      Patients with 37 known and 19 novel HCV subtypes were included in these analyses. Overall, 28% (range 9% to 61% depending on genotype) had detectable NS5A class RASs at baseline, using a 15% sequencing assay cut-off. There was no significant effect of baseline NS5A class RASs on sustained virologic response at week 12 (SVR12) with sofosbuvir/velpatasvir; the SVR12 rate in the presence of NS5A class RASs was 100% and 97%, in patients with GT1a and GT1b infection, respectively, and 100% in patients with GT2 and GT4–6 infections. In GT3 infection, the SVR rate was 93% and 98% in patients with and without baseline NS5A class RASs, respectively. The overall virologic failure rate was low (20/1,778 = 1.1%) in patients treated with sofosbuvir/velpatasvir. Single NS5A class resistance was observed at virologic failure in 17 of the 20 patients.

      Conclusions

      Sofosbuvir/velpatasvir taken for 12 weeks once daily resulted in high SVR rates in patients infected with GT1–6 HCV, irrespective of baseline NS5A RASs. NS5A inhibitor resistance, but not sofosbuvir resistance, was detected in the few patients with virologic failure. These data highlight the high barrier to resistance of this regimen for the treatment of chronic HCV across all genotypes in the vast majority of patients.

      Lay summary

      Sofosbuvir/velpatasvir taken once daily for 12 weeks resulted in high sustained virologic response rates in patients infected with HCV, irrespective of the presence of NS5A resistance-associated variants prior to treatment. Single class NS5A inhibitor resistance, but not sofosbuvir resistance, was detected in the few patients with virologic failure. These data highlight the high barrier to resistance of this regimen for the treatment of chronic HCV across all genotypes in the vast majority of patients.

      Graphical abstract

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Rao V.B.
        • Johari N.
        • du Cros P.
        • Messina J.
        • Ford N.
        • Cooke G.S.
        Hepatitis C seroprevalence and HIV co-infection in sub-Saharan Africa: a systematic review and meta-analysis.
        Lancet Infect Dis. 2015; 15: 819-824
        • Polaris Observatory HCV Collaborators
        Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.
        Lancet Gastroenterol Hepatol. 2017; 2: 161-176
      1. World Health Organization. Hepatitis C fact sheet, April 2017. http://www.who.int/mediacentre/factsheets/fs164/en/

        • Liang T.J.
        • Ghany M.G.
        Current and future therapies for hepatitis C virus infection.
        N Engl J Med. 2013; 368: 1907-1917
        • Smith D.B.
        • Bukh J.
        • Kuiken C.
        • Muerhoff A.S.
        • Rice C.M.
        • Stapleton J.T.
        • et al.
        Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource.
        Hepatology. 2014; 59: 318-327
        • Messina J.P.
        • Humphreys I.
        • Flaxman A.
        • Brown A.
        • Cooke G.S.
        • Pybus O.G.
        • et al.
        Global distribution and prevalence of hepatitis C virus genotypes.
        Hepatology. 2015; 61: 77-87
        • Kaneko T.
        • Tanji Y.
        • Satoh S.
        • Hijikata M.
        • Asabe S.
        • Kimura K.
        • et al.
        Production of two phosphoproteins from the NS5A region of the hepatitis C viral genome.
        Biochem Biophys Res Commun. 1994; 205: 320-326
      2. He Y, Staschke KA, Tan SL: HCV NS5A: A Multifunctional Regulator of Cellular Pathways and Virus Replication. In: Tan SL, ed. Hepatitis C Viruses: Genomes and Molecular Biology. Norfolk (UK), 2006.

        • Lawitz E.J.
        • Dvory-Sobol H.
        • Doehle B.P.
        • Worth A.S.
        • McNally J.
        • Brainard D.M.
        • et al.
        Clinical resistance to velpatasvir (GS-5816), a novel pan-genotypic inhibitor of the hepatitis C virus NS5A protein.
        Antimicrob Agents Chemother. 2016; 60: 5368-5378
        • Feld J.J.
        • Jacobson I.M.
        • Hezode C.
        • Asselah T.
        • Ruane P.J.
        • Gruener N.
        • et al.
        Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection.
        N Engl J Med. 2015; 373: 2599-2607
        • Foster G.R.
        • Afdhal N.
        • Roberts S.K.
        • Brau N.
        • Gane E.J.
        • Pianko S.
        • et al.
        Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection.
        N Engl J Med. 2015; 373: 2608-2617
      3. Wyles D, Brau, N, Kottilil, S, Daar, E, Workowski, K, Luetkemeyer, A, et al. Sofosbuvir/Velpatasvir for 12 Weeks in Patients Coinfected With HCV and HIV-1: The ASTRAL-5 Study. In: The International Liver Congress™ EASL - European Association for the Study of the Liver; 2016 13–17 April 2016; Barcelona, Spain; 2016.

        • Jacobson I.M.
        • Lawitz E.
        • Gane E.J.
        • Willems B.E.
        • Ruane P.J.
        • Nahass R.G.
        • et al.
        Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials.
        Gastroenterology. 2017;
        • Zeuzem S.
        • Mizokami M.
        • Pianko S.
        • Mangia A.
        • Han K.H.
        • Martin R.
        • et al.
        NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome.
        J Hepatol. 2017; 66: 910-918
        • I-h Shih.
        • Vliegen I.
        • Peng B.
        • Yang H.
        • Hebner C.
        • Paeshuyse J.
        • et al.
        Mechanistic characterization of GS-9190 (tegobuvir), a novel non-nucleoside inhibitor of hepatitis C virus NS5B polymerase.
        Antimicrob Agents Chemother. 2011; 55: 4196-4203
        • Lohmann V.
        • Korner F.
        • Koch J.
        • Herian U.
        • Theilmann L.
        • Bartenschlager R.
        Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line.
        Science. 1999; 285: 110-113
        • Schreiber J.
        • McNally J.
        • Chodavarapu K.
        • Svarovskaia E.
        • Moreno C.
        Treatment of a patient with genotype 7 HCV infection with sofosbuvir and velpatasvir.
        Hepatology. 2016;
      4. Cheng G, Yu M, Peng B, Lee Y-J, Gong R, Trejo-Martin A, et al. GS-5816, a second-generation HCV NS5A inhibitor with potent antiviral activity, broad genotypic coverage, and a high resistance barrier. Abstr 48th Annual Meeting of the European Association for the Study of the Liver http://wwwnataporg/2013/EASL/EASL_34htm. 2013.

        • Nelson D.R.
        • Cooper J.N.
        • Lalezari J.P.
        • Lawitz E.
        • Pockros P.J.
        • Gitlin N.
        • et al.
        All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
        Hepatology. 2015; 61: 1127-1135
        • Fridell R.A.
        • Wang C.
        • Sun J.H.
        • O'Boyle 2nd, D.R.
        • Nower P.
        • Valera L.
        • et al.
        Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.
        Hepatology. 2011; 54: 1924-1935
        • Liu R.
        • Curry S.
        • McMonagle P.
        • Yeh W.W.
        • Ludmerer S.W.
        • Jumes P.A.
        • et al.
        Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir.
        Antimicrob Agents Chemother. 2015; 59: 6922-6929
        • Krishnan P.
        • Beyer J.
        • Mistry N.
        • Koev G.
        • Reisch T.
        • DeGoey D.
        • et al.
        In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A.
        Antimicrob Agents Chemother. 2015; 59: 979-987